OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma

Share "OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma"

N/A

Protected

Studieår: 2022

Info

Nedlasting

Protected

Academic year: 2022

Share "OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma"

Copied!

Laster.... (Se fulltekst nå)

Last ned nå ( 11 sider )

Fulltekst

Referanser

Last ned nå ( PDF - 11 sider - 2.80 MB )

RELATERTE DOKUMENTER

$Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial$

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

1 Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients Running title: KMP vs VMP for newly diagnosed multiple myeloma Thierry Facon,

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

$Isatuximab for relapsed / refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study$

Isatuximab for relapsed / refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study

$The cost-effectiveness of pomalidomide for treating patients with relapsed multiple myeloma refractory to both lenalidomide and bortezomib$

The cost-effectiveness of pomalidomide for treating patients with relapsed multiple myeloma refractory to both lenalidomide and bortezomib

$Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma$

Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group